IL12RB2

IL12RB2 encodes the IL-12 receptor β2 subunit, a signaling component that transduces IL-12 stimulation into STAT4 phosphorylation and IFN-γ production, physiologically restraining aberrant B-cell activation and supporting IFN-γ-dependent tumor surveillance: its genetic inactivation in mice produces spontaneous autoimmunity, B-cell tumors, and lung carcinoma alongside IFN-γ deficiency and IL-6 upregulation (PMID:16081683). IL12RB2 expression is epigenetically gated. In Th17 cells the locus carries repressive H3K27 trimethylation that is removed upon activation or immunization, permitting IL-12R β2 upregulation; subsequent IL-12 signaling demethylates the Tbx21/T-bet locus and deviates Th17 cells toward a Th1-like profile (PMID:21307296). During human CD4 T cell activation this derepression depends on the H3K27 demethylase JMJD3, whose inhibition prevents promoter demethylation and impairs IL12RB2 induction (PMID:28947543). Promoter and intergenic-enhancer polymorphisms further tune expression: SNPs at −1035/−1023 create differential binding sites for JunB, GATA-3, and MEF-2, with the −1023G allele forming an AP-1 site that enhances JunB binding, and JunB knockdown abolishes haplotype-specific promoter activity (PMID:26552659). These variants act in a cell-type-specific manner, lowering transcriptional output and IFN-γ in T cells while raising both in NK cells (PMID:18771340), and an enhancer SNP in the IL23R–IL12RB2 intergenic region alters reporter activity, H3K4me1, and the proportion of Th1 cells (PMID:26916345).

1. 2005 High

   Established the in vivo physiological role of IL-12Rβ2 signaling, showing it is required to restrain B-cell activation and sustain IFN-γ-dependent tumor surveillance rather than merely being a cytokine receptor subunit.

   Evidence Il12rb2 knockout mouse with histopathology, serum autoantibody assays, and splenocyte cytokine measurement

   PMID:16081683

   Open questions at the time

   • Does not resolve which downstream effectors mediate autoimmunity versus tumor phenotypes
   • IL-6 upregulation mechanism downstream of receptor loss not defined
   • Cell-intrinsic versus extrinsic contributions not dissected
2. 2008 Medium

   Showed that IL12RB2 promoter SNPs functionally alter transcription and IFN-γ output in a cell-type-dependent manner, linking genetic variation to differential signaling capacity in T versus NK cells.

   Evidence Luciferase reporter assays in NK3.3 and Jurkat cells plus IFN-γ ELISA in primary cells from genotyped donors

   PMID:18771340

   Open questions at the time

   • Transcription factors responsible for the cell-type difference not identified in this study
   • Reporter activity may not reflect endogenous chromatin context
3. 2011 Medium

   Identified H3K27me3 as the repressive mark gating IL12RB2 expression in Th17 cells and connected its activation-dependent removal to IL-12-driven Th1 deviation.

   Evidence ChIP for H3K27me3/H3K4me3 at Il12rb2 and Tbx21 loci in ex vivo and in vitro Th17 cells with functional deviation assay

   PMID:21307296

   Open questions at the time

   • Enzyme removing H3K27me3 not identified here
   • Single-lab finding
   • Stability of deviated phenotype not addressed
4. 2015 Medium

   Defined JunB as a key transcriptional regulator of IL12RB2 and showed how the −1023G allele creates an AP-1 site that enhances JunB recruitment.

   Evidence TF-binding ELISA, luciferase reporter assays, and JunB siRNA knockdown in Jurkat and NK3.3 cells

   PMID:26552659

   Open questions at the time

   • Roles of GATA-3 and MEF-2 not functionally validated
   • Endogenous gene-level effect of JunB not confirmed
5. 2015 Low

   Linked IL12RB2 promoter genotype to downstream IL-12 receptor signaling strength via STAT4 phosphorylation.

   Evidence STAT4 phosphorylation assay in T cell blasts stratified by IL12RB2 genotype

   PMID:26547104

   Open questions at the time

   • Single correlative functional assay without mechanistic dissection
   • Methodological detail limited
   • Causality from SNP to signaling not established
6. 2016 Medium

   Mapped a disease-associated enhancer in the IL23R–IL12RB2 intergenic region whose risk allele alters chromatin state and Th1 proportions without changing IL12RB2 mRNA.

   Evidence Luciferase reporter, EMSA, H3K4me1 ChIP, flow cytometry, and RT-qPCR in CD4+ T cells from genotyped donors

   PMID:26916345

   Open questions at the time

   • The trans-acting factor binding the enhancer not identified
   • Target gene of the enhancer ambiguous given unchanged IL12RB2 mRNA
   • Mechanism linking enhancer to Th1 skewing unresolved
7. 2017 Medium

   Identified JMJD3 as the H3K27 demethylase required for IL12RB2 derepression during human T cell activation, providing the enzymatic basis for the activation-dependent epigenetic switch.

   Evidence H3K27me3 ChIP-seq in naive/memory CD4 T cells plus JMJD3 inhibitor with IL12RB2 expression quantification

   PMID:28947543

   Open questions at the time

   • Recruitment mechanism of JMJD3 to the locus unknown
   • Inhibitor specificity not fully excluded
   • Single-lab finding

• How epigenetic gating (H3K27me3/JMJD3), SNP-driven transcription factor recruitment, and downstream STAT4 signaling integrate to set quantitative IL-12Rβ2 output in distinct lymphocyte lineages remains unresolved.
• No structural or biochemical characterization of the receptor itself in this corpus
• No unified model linking promoter and intergenic-enhancer variants to in vivo phenotypes
• Direct molecular partners of IL-12Rβ2 not defined in the timeline